MetaCap

Belite Bio (BLTE) vs PTC Therapeutics (PTCT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Belite Bio (BLTE) has outperformed PTC Therapeutics (PTCT) over the past year, gaining 5.7% versus a loss of 28.1%. Belite Bio is the larger company by market cap ($5.17 billion vs $4.71 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BLTE+5.66%PTCT-28.10%
+65%+16%-33%
Nov 21, 20251 yearNov 20, 2026
BLTE+1102.83%PTCT+59.69%
+1817%+840%-136%
Apr 25, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BLTE versus PTCT key metrics
MetricBLTEPTCT
Share price$127.38$56.42
Market cap$5.17B$4.71B
1-day change-15.65%-3.27%
YTD return-20.37%-25.72%
1-year return+5.66%-28.10%
5-year return—+48.24%
Forward P/E—17.69
EPS (TTM)$-2.84$-1.47
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.73B
Revenue growth (YoY)—+114.51%
Net income (latest FY)$-77.61M$682.64M
Operating margin—50.09%
Net margin—39.44%
52-week high$200.00$90.87
52-week low$115.41$56.18
Distance from 52-week high-36.31%-37.91%
Analyst consensusstrong_buybuy
Avg. price target upside+82.92%+78.08%
Average volume195.65K1.07M
Shares outstanding40.61M83.54M
Employees41991
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BLTE has outperformed PTCT by 33.8 percentage points over the past year.

About Belite Bio

BLTE stock →

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees

About PTC Therapeutics

PTCT stock →

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.

Health Care · Biotechnology: Pharmaceutical Preparations · 991 employees

BLTE vs PTCT FAQ

Which is bigger, Belite Bio or PTC Therapeutics?

Belite Bio (BLTE) is larger, with a market capitalization of $5.17B compared with $4.71B for PTC Therapeutics (PTCT).

Which stock has performed better over the past year, BLTE or PTCT?

BLTE returned +5.66% over the past 12 months, compared with -28.10% for PTCT (price return, excluding dividends). Past performance does not predict future results.

Are Belite Bio and PTC Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons